Discover how DNDI-6174, a novel drug candidate, targets the cytochrome bc1 complex to combat visceral leishmaniasis, a deadly parasitic disease affecting millions worldwide.
Explore how amphotericin B lipid complex transformed treatment for antimony-unresponsive visceral leishmaniasis in India, with clinical evidence and mechanism of action.
How microarray technology is revolutionizing the fight against Visceral Leishmaniasis through gene expression analysis